| CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas (NCT03383965) | Immune Cell, Inc. | 2017-03-01 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT (NCT03018223) | H. Lee Moffitt Cancer Center and Research Institute | 2017-01-31 |
| A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) (NCT03033914) | Memorial Sloan Kettering Cancer Center | 2017-01-25 |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery (NCT02955043) | University of Wisconsin, Madison | 2016-12-22 |
| Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant (NCT02115126) | David Rizzieri, MD | 2016-12-01 |
| Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure (NCT03323541) | University Hospital, Brest | 2016-11-03 |
| Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (NCT02763254) | Cell Medica Ltd | 2016-11-01 |
| Genetic Study of Families With High Frequency of Hodgkin Lymphoma (NCT02795013) | St. Jude Children's Research Hospital | 2016-08-17 |
| Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) (NCT02624388) | University of Virginia | 2016-08-01 |
| Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool (NCT02791217) | Assuta Medical Center | 2016-06-01 |
| Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) (NCT02684292) | Merck Sharp & Dohme LLC | 2016-05-23 |
| Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT02665650) | Affimed GmbH | 2016-05-01 |
| Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (NCT02973113) | Baylor College of Medicine | 2016-02-16 |
| Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (NCT02508038) | University of Wisconsin, Madison | 2016-02-12 |
| Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (NCT02506933) | City of Hope Medical Center | 2015-12-21 |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02566304) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-11-13 |
| Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma (NCT02624258) | University of Pennsylvania | 2015-11-01 |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma (NCT02572167) | Seagen Inc. | 2015-10-31 |
| Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (NCT02432235) | ADC Therapeutics S.A. | 2015-10-05 |
| Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies (NCT02507479) | Sheba Medical Center | 2015-09-01 |
| Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma (NCT02191930) | University of Cologne | 2015-09-01 |
| Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma (NCT02505269) | Massachusetts General Hospital | 2015-08-07 |
| Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) (NCT02453594) | Merck Sharp & Dohme LLC | 2015-06-10 |
| Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia (NCT02473523) | St. Jude Children's Research Hospital | 2015-06-01 |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma (NCT02424968) | Robert Lowsky | 2015-06-01 |
| GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02321592) | University of Cologne | 2015-05-01 |
| Brentuximab for Newly Diagnosed Hodgkin Disease (NCT02398240) | Mitchell Cairo | 2015-05-01 |
| Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD (NCT02298283) | The Lymphoma Academic Research Organisation | 2015-04-01 |
| Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. (NCT02292979) | The Lymphoma Academic Research Organisation | 2015-03-01 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (NCT02362035) | Acerta Pharma BV | 2015-02-20 |
| Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma (NCT03480087) | A.O.U. Città della Salute e della Scienza | 2015-01-01 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02129582) | Case Comprehensive Cancer Center | 2014-11-05 |
| A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer (NCT02256137) | St. Jude Children's Research Hospital | 2014-10-08 |
| Detection and Characterization of Residual Masses in Lymphomas (NCT02300402) | The Lymphoma Academic Research Organisation | 2014-10-01 |
| Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors (NCT02080416) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-07-01 |
| Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients (NCT02280993) | Marjolein Spiering | 2014-05-01 |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma (NCT01990534) | Millennium Pharmaceuticals, Inc. | 2014-03-14 |
| Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients (NCT02098512) | New York Medical College | 2014-03-01 |
| A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) (NCT01953692) | Merck Sharp & Dohme LLC | 2013-11-22 |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (NCT01634217) | Masonic Cancer Center, University of Minnesota | 2013-11-08 |
| Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies (NCT01998035) | Columbia University | 2013-11-01 |
| A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma (NCT01950364) | Millennium Pharmaceuticals, Inc. | 2013-11-01 |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (NCT01947140) | Jennifer Amengual | 2013-09-09 |
| Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma (NCT01943682) | Children's Hospital Medical Center, Cincinnati | 2013-09-01 |
| Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study. (NCT06295211) | Federico II University | 2013-09-01 |
| Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies (NCT01900509) | St. Jude Children's Research Hospital | 2013-08-01 |
| Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (NCT01908387) | Celgene Corporation | 2013-07-01 |
| Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas (NCT01793233) | Children's Oncology Group | 2013-06-17 |
| Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) (NCT01652261) | European Organisation for Research and Treatment of Cancer - EORTC | 2013-05-01 |
| Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (NCT01868451) | Memorial Sloan Kettering Cancer Center | 2013-05-01 |
| Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma (NCT02275598) | University of Modena and Reggio Emilia | 2013-04-01 |
| Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. (NCT02227433) | Fondazione Italiana Linfomi - ETS | 2013-02-04 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma (NCT01712490) | Takeda | 2012-11-09 |
| Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma (NCT01569204) | University of Cologne | 2012-10-01 |
| An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (NCT01592370) | Bristol-Myers Squibb | 2012-08-02 |
| Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01453504) | University of Cologne | 2012-08-01 |
| Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) (NCT01657331) | Columbia University | 2012-07-01 |
| BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology (NCT01660776) | Rennes University Hospital | 2012-06-07 |
| Double Cord Versus Haploidentical (BMT CTN 1101) (NCT01597778) | Medical College of Wisconsin | 2012-06-01 |
| Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma (NCT01534078) | Massachusetts General Hospital | 2012-03-01 |
| Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases (NCT01447056) | Baylor College of Medicine | 2012-02-01 |
| HD17 for Intermediate Stage Hodgkin Lymphoma (NCT01356680) | University of Cologne | 2012-01-13 |
| Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (NCT01333046) | Baylor College of Medicine | 2012-01-01 |
| Music Therapy on Nausea and Pain for Autologous Stem Cell (NCT01487031) | Case Comprehensive Cancer Center | 2011-11-01 |
| Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (NCT01452334) | Bristol-Myers Squibb | 2011-11-01 |
| Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma (NCT01468311) | National Cancer Institute (NCI) | 2011-10-11 |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) (NCT01351545) | Center for International Blood and Marrow Transplant Research | 2011-10-01 |
| Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma (NCT01393106) | Gilead Sciences | 2011-09-01 |
| IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma (NCT01333605) | Fudan University | 2011-04-01 |
| Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma (NCT01217229) | Daiichi Sankyo | 2011-03-03 |
| Screening for Coronary Artery Disease After Mediastinal Irradiation (NCT01271127) | Leiden University Medical Center | 2011-01-01 |
| A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies (NCT01263899) | S*BIO | 2010-12-01 |
| 124I-FIAU Imaging in EBV and KSHV Associated Cancers (NCT00982449) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2010-12-01 |
| A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL) (NCT01523847) | Fondazione Italiana Linfomi - ETS | 2010-11-01 |
| Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma (NCT01231269) | Universitaire Ziekenhuizen KU Leuven | 2010-11-01 |
| Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma (NCT01165645) | Mayo Clinic | 2010-11-01 |
| A Study to Assess AFM13 in Patients With Hodgkin Lymphoma (NCT01221571) | Affimed GmbH | 2010-10-01 |
| Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients (NCT01056679) | University of Cologne | 2010-04-01 |
| Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients (NCT01228461) | Vanderbilt University | 2010-02-01 |
| Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. (NCT01022996) | Novartis Pharmaceuticals | 2009-12-01 |
| HD16 for Early Stage Hodgkin Lymphoma (NCT00736320) | University of Cologne | 2009-11-01 |
| Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas (NCT01030900) | National Cancer Institute (NCI) | 2009-10-22 |
| Brazilian Prospective Hodgkin Lymphoma Registry (NCT02589548) | Universidade Federal do Rio de Janeiro | 2009-10-01 |
| R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma (NCT00992030) | Fondazione Michelangelo | 2009-09-01 |
| Proton Therapy for Hodgkin Lymphoma (NCT00850200) | University of Florida | 2009-08-01 |
| Methionine PET/CT Studies In Patients With Cancer (NCT00840047) | St. Jude Children's Research Hospital | 2009-07-20 |
| Gonadal Toxicity in Women With Hodgkin Lymphoma (NCT01008735) | Gruppo Italiano Studio Linfomi | 2009-07-01 |
| Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma (NCT00846742) | St. Jude Children's Research Hospital | 2009-06-05 |
| Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma (NCT00928018) | Dana-Farber Cancer Institute | 2009-06-01 |
| Unrelated Umbilical Cord Blood (UBC)Transplantation (NCT01768845) | West Virginia University | 2009-02-03 |
| Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma (NCT00722865) | Massachusetts General Hospital | 2008-09-01 |
| Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT (NCT00709592) | Virginia Commonwealth University | 2008-07-21 |
| Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma (NCT00722488) | Millennium Pharmaceuticals, Inc. | 2008-06-01 |
| Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL) (NCT00795613) | Ospedale Santa Croce-Carle Cuneo | 2008-06-01 |
| Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR (NCT01611298) | Robert Krance | 2008-03-01 |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies (NCT00566696) | St. Jude Children's Research Hospital | 2007-12-14 |
| Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma (NCT00606645) | Xencor, Inc. | 2007-12-01 |
| MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma (NCT00543582) | Mirati Therapeutics Inc. | 2007-10-01 |